ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Sanofi Finalizes Sale Of Dermik To Valeant Pharmaceuticals

PARIS -(Dow Jones)- French drug company Sanofi-Aventis (SAN.FR) announced Monday the finalization of the sale of its Canadian dermatology business, Dermik, to Valeant Pharmaceuticals International Inc. (VRX) for $422.5 million. In a statement, Sanofi said the transaction includes an aesthetic and therapeutic business in the U.S. and Canada, as well as an aesthetic business around the world. Sanofi's Canadian unit will continue its operations in Greater Montreal, said the company. -By Nadya Masidlover, Dow Jones Newswires; +33 1 4017 1740; nadya.masidlover@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
07/28/201617:12:36Current Report Filing (8-k)
07/28/201617:00:00Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh...
07/28/201617:00:00Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh...
07/28/201601:00:00Pharming Reports on Financial Results for the First Six Months...
07/26/201608:30:00Progenics Receives $50 Million Milestone Payment Following FDA...
07/22/201617:00:00Toronto Stocks Rise as Earnings Offset Falling Oil and Gold Prices
07/22/201602:00:00Valeant Pharmaceuticals Receives Complete Response Letter From...
07/22/201602:00:00Valeant Pharmaceuticals Receives Complete Response Letter From...
07/19/201621:40:00Valeant Gets FDA OK for Anticonstipation Tablets Developed by...
07/19/201621:02:00Valeant Gets FDA OK for Anticonstipation Tablets Developed by...
07/19/201619:19:00Valeant, Progenics Shares Rise on Constipation Drug Approval
07/19/201618:04:00Valeant and Progenics Announce FDA Approves RELISTOR® Tablets...
07/19/201618:04:00Valeant and Progenics Announce FDA Approves RELISTOR® Tablets...
07/19/201617:48:00Valeant Gets FDA Panel Recommendation for Psoriasis Drug
07/19/201616:27:00FDA Advisory Committee Recommends Approval Of Brodalumab For...
07/19/201616:27:00FDA Advisory Committee Recommends Approval Of Brodalumab For...
07/18/201601:00:00Pharming Announces Positive Results from Randomized Controlled...
07/15/201608:00:00Valeant Pharmaceuticals Announces Second Quarter Results Conference...
07/15/201608:00:00Valeant Pharmaceuticals Announces Second Quarter Results Conference...
07/14/201609:43:00Valeant's Ex-CEO Michael Pearson Sells Nearly $100 Million in...

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad